From: healthline.com Human epidermal growth factor receptor 2 (HER2) is a protein on the surface of breast cells. Its usual function is to promote cellular growth and division. Some breast cancers have higher-than-normal levels of HER2 protein receptors. These are called HER2-positive breast cancers. However, only around 13%Trusted Source of breast cancers are HER2-positive. Continue reading below to learn the …
What Does It Mean to Have HER2-Negative Breast Cancer?
From; Healthline.com Human epidermal growth factor receptor 2 (HER2) is a protein that’s found on the surface of breast cells. Its normal function is to promote cellular growth and division. Some breast cancers have higher-than-normal levels of HER2 protein receptors. These are called HER2-positive breast cancers. However, only a low percentage of breast cancers are HER2-positive. Most breast cancers are …
Breaking Down the Treatment Options for HER2-Negative Breast Cancer
From: healthline.com Treatment options for HER2-negative breast cancer include surgery, hormone therapy, radiation therapy, targeted therapy, chemotherapy, and immunotherapy. Treatment for HER2-negative breast cancer will depend on factors such as hormone receptor status, cancer stage, and your age and overall health. The goal of treatment for HER2-negative breast cancer can vary based on the extent of your cancer. It may …
The Evolving Pharmacist Role in HER2-Negative Adjuvant Breast Cancer Therapy
By: Alexandra Gerlach, Associate Editor, Julia Ziegengeist, PharmD, BCOP From: pharmacytimes.com In an interview with Pharmacy Times,® Julia Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator of solid tumor oncology at the Levine Cancer Institute, Atrium Health, discussed data from her presentation at the HOPA Annual Meeting 2025 about adjuvant and neoadjuvant treatment of early-stage human epidermal growth factor receptor 2-negative (HER2-) …
Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer
By: Ryan Scott From: onclive.com Robust phase 3 trial data have led to the integration of CDK4/6 inhibitors into the hormone receptor–positive, HER2-negative breast cancer treatment paradigm, and the continued emergence of data have helped answer selection and sequencing questions about agents such as ribociclib (Kisqali), abemaciclib (Verzenio), and palbociclib (Ibrance), according to Lubna Naaz Chaudhary, MD, MS. “In our …
Clinical study confirms tissue stiffening in breast cancer can drive metastasis
By: Mark Febbo, University of Arizona Cancer Center From: healthsciences.arizona.edu A study published in Clinical Cancer Research confirmed that tissue stiffening in the most common types of breast cancer, HER2-negative, can directly cause disease progression and metastasis, leading to detrimental outcomes for patients. The work was a collaboration between researchers at the University of Arizona Health Sciences and clinicians in Spain. Researchers …
ADC Choices Require Discretion in HER2-Negative MBC
By: Kyle Doherty From: onclive.com With multiple antibody drug conjugate (ADC) options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies, according to a presentation by Joshua Z. Drago, MD, MS, during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow® conference.1 “ADCs are being developed …
FDA Grants Priority Review to NDA for Elacestrant in ER+/HER2- Advanced or mBC
By: Nichole Tucker astaastFrom: targetedonc.com Positive findings from the phase 3 EMERALD study led to a new drug application for elacestrant as treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The FDA has granted the application priority review. The FDA has accepted a new drug application for the selective estrogen receptor degrader, elacestrant, and granted it priority review …
Erica Mayer, MD, on Updated HER2- Breast Cancer Guidelines
By: Jeff Minerd From: medpagetoday.com New ASCO recommendations highlight genomic profiling and novel agents ASCO has published two sets of updated guidelines for patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer, both in the Journal of Clinical Oncology. One of the updates (Burstein et al.) covers endocrine treatment and targeted therapy for patients with hormone receptor …
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
From: businesswire.com Study will evaluate the efficacy and safety of NERLYNX® plus XELODA® in patients selected by the CELsignia® Test who have metastatic HER2-negative breast cancer with brain metastases The unique tumor insights CELsignia generates enable identification of new potential applications for targeted therapies and development of potential first-in-class drugs Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing an …